Bipolar androgen therapy in prostate cancer: Current evidences and future perspectives
- 1 August 2020
- journal article
- review article
- Published by Elsevier in Critical Reviews in Oncology/Hematology
- Vol. 152, 102994
Abstract
No abstract availableKeywords
This publication has 49 references indexed in Scilit:
- Increased Survival with Enzalutamide in Prostate Cancer after ChemotherapyNew England Journal of Medicine, 2012
- Androgen Receptor Gene Expression in Prostate Cancer Is Directly Suppressed by the Androgen Receptor Through Recruitment of Lysine-Specific Demethylase 1Cancer Cell, 2011
- Abiraterone and Increased Survival in Metastatic Prostate CancerNew England Journal of Medicine, 2011
- The androgen receptor fuels prostate cancer by regulating central metabolism and biosynthesisThe EMBO Journal, 2011
- Androgen-induced TOP2B-mediated double-strand breaks and prostate cancer gene rearrangementsNature Genetics, 2010
- Phase 1 Trial of High-Dose Exogenous Testosterone in Patients with Castration-Resistant Metastatic Prostate CancerEuropean Urology, 2009
- A Randomized Phase 1 Study of Testosterone Replacement for Patients with Low-Risk Castration-Resistant Prostate CancerEuropean Urology, 2009
- AMPK Phosphorylation of Raptor Mediates a Metabolic CheckpointMolecular Cell, 2008
- Androgen receptor as a licensing factor for DNA replication in androgen-sensitive prostate cancer cellsProceedings of the National Academy of Sciences, 2006
- Androgen receptor gene amplification and protein expression in hormone refractory prostate cancerBritish Journal of Cancer, 2003